<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=348185225613720&amp;ev=PageView&amp;noscript=1">
Skip to content


Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel Sequencing

About the Case Study

Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This case study looks at how Azenta utilized the PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.

This case study discusses:

  • Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
  • Generation of highly accurate consensus sequences
  • Identification of approximately 20,000 structural variants
  • Future applications

Download Now

For technical support questions, please contact our Next Generation Sequencing team

(877) 436-3949 ext. 1 | ngs@azenta.com